{"id":11,"date":"2025-10-03T15:44:26","date_gmt":"2025-10-03T06:44:26","guid":{"rendered":"https:\/\/site.convention.co.jp\/actajasthcc2026\/?page_id=11"},"modified":"2025-10-30T14:32:36","modified_gmt":"2025-10-30T05:32:36","slug":"message","status":"publish","type":"page","link":"https:\/\/site.convention.co.jp\/actajasthcc2026\/message\/","title":{"rendered":"Welcome Message"},"content":{"rendered":"<div id=\"pl-11\"  class=\"panel-layout\" ><div id=\"pg-11-0\"  class=\"panel-grid panel-no-style\" ><div id=\"pgc-11-0-0\"  class=\"panel-grid-cell\" ><div id=\"panel-11-0-0-0\" class=\"so-panel widget widget_text panel-first-child panel-last-child\" data-index=\"0\" ><div class=\"panel-widget-style panel-widget-style-for-11-0-0-0\" >\t\t\t<div class=\"textwidget\"><p>President, ACTA2026 and JAST-HCC International Symposium2026<br \/>\nMasatoshi Kudo, MD, PhD<br \/>\nProfessor and Chairman,<br \/>\nDepartment of Gastroenterology and Hepatology<br \/>\nKindai University Faculty of Medicine<\/p>\n<\/div>\n\t\t<\/div><\/div><\/div><div id=\"pgc-11-0-1\"  class=\"panel-grid-cell\" ><div id=\"panel-11-0-1-0\" class=\"so-panel widget widget_media_image panel-first-child panel-last-child\" data-index=\"1\" ><img width=\"720\" height=\"960\" src=\"https:\/\/site.convention.co.jp\/actajasthcc2026\/wp\/wp-content\/uploads\/2025\/10\/img01_message.jpg\" class=\"image wp-image-14  attachment-full size-full\" alt=\"\" decoding=\"async\" loading=\"lazy\" style=\"max-width: 100%; height: auto;\" srcset=\"https:\/\/site.convention.co.jp\/actajasthcc2026\/wp\/wp-content\/uploads\/2025\/10\/img01_message.jpg 720w, https:\/\/site.convention.co.jp\/actajasthcc2026\/wp\/wp-content\/uploads\/2025\/10\/img01_message-225x300.jpg 225w\" sizes=\"(max-width: 720px) 100vw, 720px\" \/><\/div><\/div><\/div><div id=\"pg-11-1\"  class=\"panel-grid panel-no-style\" ><div id=\"pgc-11-1-0\"  class=\"panel-grid-cell\" ><div id=\"panel-11-1-0-0\" class=\"so-panel widget widget_text panel-first-child panel-last-child\" data-index=\"2\" >\t\t\t<div class=\"textwidget\"><p>On behalf of the Asian Conference on Tumor Ablation (<span style=\"font-weight:bold;\">ACTA<\/span>), it is my great honor to announce the upcoming <span style=\"font-weight:bold;\">12th ACTA 2026<\/span>, which will be held in Kyoto, Japan, from November 26 to 28, 2026. Since the 1st ACTA was hosted in Japan by Professor Shuichiro Shiina, this will mark the 4th time ACTA takes place in Japan.<\/p>\n<p>In conjunction with ACTA2026, we are pleased to also host the International Symposium of the Japan Association of Systemic Therapy for HCC (<span style=\"font-weight:bold;\">JAST-HCC<\/span>). Therefore, the theme of this year\u2019s congress is \u201c<span style=\"font-weight:bold;\">From LRT to Systemic Therapy<\/span>.\u201d<\/p>\n<p>Over the three days of ACTA2026, we will focus on tumor ablation in a wide range of fields including hepatobiliary-pancreatic, urological, thoracic, gynecologic, musculoskeletal, thyroid, and head &#038; neck. The program will feature educational lectures, free paper presentations, and the latest evidence on combined therapies such as molecular targeted therapy, immunotherapy, and TACE with tumor ablation. Cutting-edge topics including Y-90 SIRT for tumor ablation, novel image guidance and navigation, the application of artificial intelligence, multidisciplinary team (MDT) approaches, and debates comparing different therapeutic modalities will also be highlighted.<\/p>\n<p>At <span style=\"font-weight:bold;\">JAST-HCC 2026<\/span>, sessions will cover the hottest topics inHCC treatment, including combination immunotherapy, first- and second-line treatment strategies, combinations of immunotherapy and locoregional therapy, conversion therapy after systemic treatment, and biomarker exploration for predicting treatment response of immunotherapy. We also plan \u201c<span style=\"font-weight:bold;\">APPLE-JAST HCC Joint Sessions<\/span>\u201d, culminating in an \u201c<span style=\"font-weight:bold;\">APPLE Consensus Meeting<\/span>\u201d on the most debated clinical questions in current systemic therapy for HCC, with the outcomes to be published as a consensus statement.<\/p>\n<p>Together, these meetings will bring experts from across Asian countries in ablation, TACE, Y-90 SIRT, and systemic therapies such as combination immunotherapy. It will be a unique opportunity to share experiences, exchange the latest evidence, and foster collaboration to further advance this rapidly developing field.<\/p>\n<p>We sincerely look forward to welcoming you to Kyoto in November 2026, a city renowned for its breathtaking autumn foliage.<\/p>\n<p>Sincerely,<\/p>\n<\/div>\n\t\t<\/div><\/div><\/div><\/div>","protected":false},"excerpt":{"rendered":"<p>President, ACTA2026 and JAST-HCC International Symposiu [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":[],"_links":{"self":[{"href":"https:\/\/site.convention.co.jp\/actajasthcc2026\/wp-json\/wp\/v2\/pages\/11"}],"collection":[{"href":"https:\/\/site.convention.co.jp\/actajasthcc2026\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/site.convention.co.jp\/actajasthcc2026\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/site.convention.co.jp\/actajasthcc2026\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/site.convention.co.jp\/actajasthcc2026\/wp-json\/wp\/v2\/comments?post=11"}],"version-history":[{"count":10,"href":"https:\/\/site.convention.co.jp\/actajasthcc2026\/wp-json\/wp\/v2\/pages\/11\/revisions"}],"predecessor-version":[{"id":52,"href":"https:\/\/site.convention.co.jp\/actajasthcc2026\/wp-json\/wp\/v2\/pages\/11\/revisions\/52"}],"wp:attachment":[{"href":"https:\/\/site.convention.co.jp\/actajasthcc2026\/wp-json\/wp\/v2\/media?parent=11"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}